MUMBAI, March 8- Indian drugmaker Ranbaxy Laboratories Ltd, reeling under a flurry of regulatory rebukes due to poor quality, has recalled more than 64,000 bottles of the generic version of a cholesterol-lowering drug in the United States after doseage mix-up was detected.» Read More
U.S. health regulators have approved GlaxoSmithKline's pill Tykerb for patients with advanced breast cancer after other treatments have failed, a company spokeswoman said on Tuesday.
J.P. Garnier, GlaxoSmithKline's chief executive officer, told CNBC's "Squawk Box" Wednesday that he expects to make the company's new drug for advanced breast cancer available to U.S. patients "within a few days."
Our celebrity trading has begun--so it's time to see where the stars "stand." Not all have traded yet but for those that have, it seems their approach to investing is more conservative than the majority of our non-celeb leaders--with more stable companies and purchases spread across multiple stocks.
Indian drugmaker Ranbaxy Laboratories said Tuesday it has submitted a bid for the generics unit of Germany's Merck but did not disclose how much it was offering.
The chief executive of Merck received compensation the company valued at $8.04 million last year, according to a regulatory filing Monday.
Painkiller Vioxx contributed to an Idaho postal worker's heart attack, a jury in Atlantic City ruled Monday, reversing the verdict in the man's first trial and hitting drugmaker Merck with a total of $47.5 million in damages.
Drugmaker Schering-Plough is buying Organon Biosciences for about $14.5 billion. Organon is part of the Dutch paint and chemical company Akzo Nobel whose shares are at a new high today on the news. Schering Chairman and CEO Fred Hassan has been saying for quite some time that he's "very much in the deal flow" on company conference calls and in interviews with CNBC, so the fact that he's making a big acquisition doesn't come as a huge shock.
Smith & Nephew, a British maker of artificial hips, said Monday it agreed to buy Plus Orthopedics Holding, a private Swiss orthopedic company, for about 1.09 billion Swiss francs ($889 million; 617 million euros) in cash to boost its share of the orthopedic reconstruction market.
Here some of Monday's big movers on European stock markets: Akzo Nobel, Alliance Boots, ICI,Swisscom and DSG International.
Akzo Nobel said on Monday it was selling its drugs unit Organon BioSciences to Schering-Plough for 11 billion euros ($14.5 billion), dropping plans to float it in a public share offer.
The CEO of Akzo Nobel may be feeling like a lottery winner this morning after making a deal with Schering-Plough.
The U.S. Food and Drug Administration on Friday issued a public health advisory for three widely-used drugs manufactured by Amgen for the treatment of anemia.
Americans may not be getting access to generic drugs, even if they are available, CNBC's David Faber reports on tonight's edition of "Business Nation."
Hollis-Eden Pharmaceuticals said the U.S. government has canceled its request for proposal for a contract for its drug to treat acute radiation syndrome, sending its shares spiraling.
Shares of Insmed plunged after the tiny biotech company said it will restructure operations due to recently settled litigation with rival Tercica, which will keep Insmed's treatment for short stature in children off the U.S. market.
CV Therapeutics said its angina drug was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
Pfizer said the FDA approved Lipitor for new uses including treating nonfatal heart attacks, fatal and nonfatal strokes, certain types of types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.
The Fast Money Five give their picks for the hottest trades. Tonight, the burning rubber rally, the call ahead of Costco earnings and more...
CV Therapeutics said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
A judge in the New Jersey Vioxx personal injury trial on Monday rejected a motion that would give one of the plaintiffs in the trial another opportunity to collect damages based on negligence from drug maker Merck.